ATE545658T1 - Verfahren zur behandlung von synovialsarkom - Google Patents

Verfahren zur behandlung von synovialsarkom

Info

Publication number
ATE545658T1
ATE545658T1 AT04713982T AT04713982T ATE545658T1 AT E545658 T1 ATE545658 T1 AT E545658T1 AT 04713982 T AT04713982 T AT 04713982T AT 04713982 T AT04713982 T AT 04713982T AT E545658 T1 ATE545658 T1 AT E545658T1
Authority
AT
Austria
Prior art keywords
synovial sarcoma
treating
treating synovial
subject
fzd10
Prior art date
Application number
AT04713982T
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Motoki Kuhara
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE545658T1 publication Critical patent/ATE545658T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04713982T 2003-07-11 2004-02-24 Verfahren zur behandlung von synovialsarkom ATE545658T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48619503P 2003-07-11 2003-07-11
PCT/JP2004/002144 WO2005004912A1 (en) 2003-07-11 2004-02-24 Method for treating synovial sarcoma

Publications (1)

Publication Number Publication Date
ATE545658T1 true ATE545658T1 (de) 2012-03-15

Family

ID=34062116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04713982T ATE545658T1 (de) 2003-07-11 2004-02-24 Verfahren zur behandlung von synovialsarkom

Country Status (5)

Country Link
EP (1) EP1648506B1 (de)
JP (1) JP4691626B2 (de)
AT (1) ATE545658T1 (de)
ES (1) ES2381841T3 (de)
WO (1) WO2005004912A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
ATE414105T1 (de) 2002-10-11 2008-11-15 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
AU2006256030B2 (en) 2005-06-10 2012-06-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
EP2511298B1 (de) * 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Behandlung von Krebs unter Verwendung von menschlichen FZD Rezeptoren
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2044123B1 (de) * 2006-06-21 2013-03-13 Oncotherapy Science, Inc. Auf tumore zielende monoklonale antikörper gegen fzd10 und anwendungen davon
AU2007319360A1 (en) * 2006-11-14 2008-05-22 Novartis Ag Methods of treating, diagnosing or detecting cancer
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
CA2844289C (en) * 2011-08-12 2020-01-14 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
JP6155255B2 (ja) * 2012-04-17 2017-06-28 Hoya株式会社 Ｆｚｄ１０結合性ペプチド
EP2911691B1 (de) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI762516B (zh) * 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9414580D0 (en) * 1994-07-19 1994-09-07 Cancer Res Campaign Tech Materials and methods relating to the diagnosis of synovial sarcomas
US5994098A (en) * 1997-06-02 1999-11-30 Smithkline Beecham Corporation Human 7-TM receptor similar to murine frizzled-6 gene
EP0943684A3 (de) * 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-ähnliche Polypeptide und Polynukleotide
GB9819681D0 (en) * 1998-09-09 1998-11-04 Smithkline Beecham Plc Novel compounds
WO2002055705A2 (en) * 2001-01-11 2002-07-18 Curagen Corp Proteins and nucleic acids encoding same
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens

Also Published As

Publication number Publication date
ES2381841T3 (es) 2012-06-01
WO2005004912A1 (en) 2005-01-20
JP4691626B2 (ja) 2011-06-01
JP2007526891A (ja) 2007-09-20
EP1648506B1 (de) 2012-02-15
EP1648506A1 (de) 2006-04-26

Similar Documents

Publication Publication Date Title
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
BR9407047A (pt) Processo para separaçao de uma proteina de uma soluçao aquosa de proteinas
ATE476990T1 (de) Cd20-bindende polypeptidzusammensetzungen
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE435012T1 (de) Verfahren zur behandlung von parkinson-krankheit
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE70190T1 (de) Verfahren zur neutralisierung von unangenehmen geruechen von tierexkrementen.
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
WO2004020668A3 (en) Method for treating synovial sarcoma
CR6528A (es) Metodo para inhibir la agregcion de proteinas amiloidesy formacion de imagenes de depositos amiloides
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60334094D1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
ATE517629T1 (de) Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems